<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302662</url>
  </required_header>
  <id_info>
    <org_study_id>MS1819/18/02</org_study_id>
    <nct_id>NCT04302662</nct_id>
  </id_info>
  <brief_title>Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs</brief_title>
  <official_title>A Multicenter, Open-label Phase 2 Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs, to Investigate the Efficacy and Safety of This Combination for the Compensation of Severe Exocrine Pancreatic Insufficiency in CF Patients Not Fully Compensated With Only PPEs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AzurRx SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AzurRx SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study sponsored by AzurRx SAS and involves testing of a new medication for&#xD;
      the compensation of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF).&#xD;
      The new medication is called MS1819 spray dried (MS1819-SD) which is a lipase produced by the&#xD;
      Lip2 gene of Yarrowia lipolytica using recombinant DNA technology.&#xD;
&#xD;
      The primary purpose of this study is to investigate the efficacy and safety of escalating&#xD;
      doses of study drug on top of a stable dose of PPEs in CF patients who are not fully&#xD;
      compensated by PPEs only.&#xD;
&#xD;
      This enzyme has demonstrated an appropriate profile to compensate the pancreatic lipase&#xD;
      (enzyme) deficiency that is common in CP (chronic pancreatitis) and CF patients.&#xD;
&#xD;
      The design of the study is open-label, meaning that all eligible patients will receive the&#xD;
      study drug MS1819-SD. The study drug dose will increase throughout the study during dose&#xD;
      escalation visits in each treatment period; study includes a total of three treatment&#xD;
      periods.&#xD;
&#xD;
      The total duration of the MS1819-SD treatment phase is of 39-51 days. The total duration of&#xD;
      patient participation in the study is of 69-81 days. Approximately 24 patients will be&#xD;
      enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">June 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential assignment: eligible patients will be receiving increased doses from lower, middle to upper range of MS1819-SD on top of a stable dose of PPEs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of fat absorption</measure>
    <time_frame>15 days</time_frame>
    <description>determination of fat absorption based on fat intake and fat excretion over 3 days on high fat meal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>81 days</time_frame>
    <description>AE, SAE, SUSAR, immunoallergic reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight of stools</measure>
    <time_frame>15 days</time_frame>
    <description>evaluation of changes in weight of stools from baseline (PPEs only) to each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of daily evacuations</measure>
    <time_frame>15 days</time_frame>
    <description>evaluation of changes in daily evacuations from baseline (PPEs only) to each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatorrhea,</measure>
    <time_frame>15 days</time_frame>
    <description>evaluation of changes in steatorrhea from baseline (PPEs only) to each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatorrhea</measure>
    <time_frame>15 days</time_frame>
    <description>evaluation of changes in creatorrhea from baseline (PPEs only) to each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>15 days</time_frame>
    <description>evaluation of changes in body weight from baseline (PPEs) to each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consistency of stools</measure>
    <time_frame>15 days</time_frame>
    <description>evaluation of consistency of stools from baseline (PPEs) to each treatment period</description>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Cystic Fibrosis Gastrointestinal Disease</condition>
  <condition>Cystic Fibrosis of Pancreas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MS1819-SD</intervention_name>
    <description>Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent form.&#xD;
&#xD;
          2. Age &gt; 12 years at the time of screening&#xD;
&#xD;
          3. Male or female.&#xD;
&#xD;
          4. Under stable dose of PPE ≥ 1 month. Stable dose is defined as dose of medication not&#xD;
             changed during this time period and the medication must be commercially available and&#xD;
             be administered in the recommended dose range.&#xD;
&#xD;
          5. A nutritional status as defined by:&#xD;
&#xD;
               1. BMI ≤ 22.0 kg/m2 for female patients&#xD;
&#xD;
               2. BMI ≤ 23.0 kg/m2 for male patients&#xD;
&#xD;
               3. BMI ≤ 50th percentile for patients 12 to &lt; 18 years of age.&#xD;
&#xD;
          6. Cystic fibrosis, based on 2 clinical features consistent with CF in the opinion of the&#xD;
             investigator AND sweat chloride concentration &gt; 60 mmol/L by pilocarpine&#xD;
             iontophoresis.&#xD;
&#xD;
          7. Faecal pancreatic elastase-1 &lt; 100 µg/g of stools at screening.&#xD;
&#xD;
          8. Baseline CFA &lt; 80% with a maximum daily dose of 10,000 lipase units/kg/day.&#xD;
&#xD;
          9. Clinically stable with no documented evidence of significant respiratory symptoms that&#xD;
             would require administration of intravenous antibiotics, oxygen supplementation, or&#xD;
             hospitalization within the 30 days of screening.&#xD;
&#xD;
         10. Male and female patients, if of childbearing potential, must use a reliable method of&#xD;
             contraception during the study. A reliable method of birth control is defined as one&#xD;
             of the following: oral or injectable contraceptives, intrauterine device,&#xD;
             contraceptive implants, tubal ligation, hysterectomy, or a double-barrier method&#xD;
             (diaphragm with spermicidal foam or jelly, or a condom), abstinence or vasectomy.&#xD;
             Periodic abstinence (calendar, symptothermal, or post-ovulation methods) is not an&#xD;
             acceptable method of contraception. The preferred and usual lifestyle of the patient&#xD;
             must also be evaluated in determining if sexual abstinence is a reliable method of&#xD;
             birth control.&#xD;
&#xD;
         11. Be considered as reliable and capable of adhering to the protocol, according to the&#xD;
             judgment of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Established or suspected fibrosing colonopathy.&#xD;
&#xD;
          2. Total or partial gastrectomy.&#xD;
&#xD;
          3. A history of solid organ transplant or significant surgical resection of the bowel;&#xD;
             significant resection of the bowel is defined as any resection of the terminal ileum&#xD;
             or ileocecal valve. Patients who have had qualitative, long-term changes in&#xD;
             nutritional status after any other bowel resection (eg, increased of new need for&#xD;
             pancreatic enzyme supplementation compared with preoperative status to maintain the&#xD;
             same nutritional status) should also be excluded.&#xD;
&#xD;
          4. Any chronic diarrheal illness unrelated to pancreatic insufficiency (eg, infectious&#xD;
             gastroenteritis, sprue, inflammatory bowel disease)&#xD;
&#xD;
          5. Known hypersensitivity or other severe reaction to any ingredient of the&#xD;
             investigational medicinal product (IMP).&#xD;
&#xD;
          6. Bilirubin &gt; 1.5 times upper limit normal (ULN).&#xD;
&#xD;
          7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 times ULN.&#xD;
&#xD;
          8. Alkaline phosphatase (ALP) &gt; 5 times ULN.&#xD;
&#xD;
          9. Gamma glutamyltransferase (GGT) &gt; 5 times ULN.&#xD;
&#xD;
         10. Signs and/or symtoms of liver cirrhosis or portal hypertension (eg, splenomegaly,&#xD;
             ascites, esophageal varices), or documented liver disease unrelated to CF&#xD;
&#xD;
         11. Patients with a known allergy to the stool marker.&#xD;
&#xD;
         12. Feeding via an enteral tube during 6 months before screening&#xD;
&#xD;
         13. Routine use of anti-diarrheals, anti-spasmodics, or cathartic laxatives, or a change&#xD;
             in chronic osmotic laxatives (eg, polyethylene glycol) regimen in the previous&#xD;
             laxative therapy within the last 12 months before screening&#xD;
&#xD;
         14. History of severe constipation with &lt; 1 evacuation/week under appropriate laxative&#xD;
             therapy within the last 12 months before screening.&#xD;
&#xD;
         15. Documentation of distal intestinal pseudo-obstruction syndrome within the last 12&#xD;
             months before screening.&#xD;
&#xD;
         16. Forced Expiratory Volume ≤ 30% at the screening visit.&#xD;
&#xD;
         17. Lactation or known pregnancy or positive pregnancy test at both screening and baseline&#xD;
             for women of childbearing potential.&#xD;
&#xD;
         18. Participation in another clinical study involving an IMP within 30 days before&#xD;
             inclusion or concomitantly with this study.&#xD;
&#xD;
         19. Poorly controlled diabetes according the investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulmonológiai Intézet Cisztás Fibrózis Részleg</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Gyermekegészségügyi Központ</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház, Mosdósi telephelye Mosdósi Gyermekrehabilitációs és Gyermekpulmonológiai Egység</name>
      <address>
        <city>Mosdós</city>
        <zip>7257</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tüdőgyógyintézet Törökbálint Gyermekpulmonológiai Osztály és Szakrendelés</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Çukurova University School of Medicine</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University School of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University School of Medicine</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cerrahpasa University School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mamara University School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan University,Meram School of Medicine</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

